20240508_华创证券_医药行业深度研究报告：创新药系列研究眼科疗法超长效时代即将来临_34页.pdf

2009 1210 2024 05 08 Age-Related Macular Degeneration AMD 2020 AMD 1.9 2023 2015 2665 AMD AMD 2020 50 AMD 180 620 VEGF AMD BCV A 140 VEGF 1-2 VEGF/Ang2 16 3 26 VEGF VEGFR EYP-1901 AXPAXLI 6 VEGF 89%60-65%6-12 AXPAXLI III EYP-1901 2024 III Eyepoint EYP-1901 EYP-1901 VEGF VEGF RGX-314 4D-150 VEGF 80%50%ABBV-RGX-314 III 2025 2026 4D-150 2025 III 2027-2028 Eyepoint/Regenxbio Ocular Therapeutix 4D Molecular Therapeutics Adverum S0360520120002 S0360524020002%()475 0.06()65,856.92 7.29()54,099.24 7.63%1M 6M 12M 5.7%-8.8%-13.6%3.1%-9.9%-4.7%2 2024-05-05&75 2023 2024 2024-05-04 20240428 IL-15 NMIBC 2024-04-28-28%-18%-9%1%23/05 23/07 23/10 23/12 24/02 24/052023-05-082024-05-07 300 2009 1210 wAMD wAMD VEGF 140 1-2 VEGF/Ang2 3 26 6 VEGF VEGF 2027-2028 Eyepoint/Regenxbio Ocular Therapeutix 4D Molecular Therapeutics Adverum 2009 1210 3 AMD.6 AMD.6 VEGF 140.7 VEGF.10.12 VEGF/Ang2.12 VEGF.14.16 EYP-1901 83%.16 AXPAXLI 12 89%.19.21 ABBV-RGX-314 wAMD.22 ADVM-022 94%.24 4D-150 63%VEGF.25 LX102 6 91%.28 KH631&KH658.28.29.31 2009 1210 4 1 AMD.6 2 AMD.6 3 AMD.7 4 AMD.8 5 VEGF AMD.8 6 wAMD.8 7 wAMD.9 8.9 9.9 10 ETDRS.10 11 OCT CRT.10 12 wAMD.11 13 VEGF.11 14 VEGF.11 15.12 16 VEGF.13 17 Vabysmo.13 18 TENAYA LUCERNE.14 19.14 20 VOYAGER.14 21 VOYAGER.14 22 wAMD.15 23 IBI302 wAMD II BCV A.16 24 IBI302 wAMD II CST.16 25 wAMD.16 26.17 27 EYE-1901.17 28 DA VIO2 BCV A.17 29 DA VIO2.17 30 DA VIO2.18 31 DA VIO2.18 32 EYP-1901 III.18 33 AXPAXLI.19 2009 1210 5 34 AXPAXLI I.20 35 AXPAXLI I.20 36 AXPAXLI I.20 37 AXPAXLI III SOL.21 38 wAMD.21 39 ABBV-RGX-314.22 40 AA VIATE.23 41 AA VIATE.23 42 RGX-314 I/IIa.23 43 RGX-314.24 44 ADVM-022.24 45 LUNA.25 46 LUNA.25 47 LUNA BCV A CST.25 48 4D-150.26 49 I/II PRISM.26 50 PRISM BCV A.27 51 PRISM CST.27 52 PRISM III.27 53 LX102 wAMD.28 54 KH631.29 55 wAMD.30 56 wAMD.31 57 wAMD.31 58 wAMD.31 2009 1210 6 AMD AMD Age-Related Macular Degeneration AMD 2023 AMD 45-85 8.69%2020 1.9 AMD AMD 4549 2.44%8589 18.98%2015 2665 AMD AMD 2020 50 AMD 180 620 AMD AMD AMD GA AMD wAMD 10%wAMD wAMD AMD 80%90%2023 GA 0.15%4549 1.09%8589 wAMD 0.24%2.79%1 AMD 2 AMD Alaska Retinal Consultant Bo Jiang et al.,Trends and disparities in disease burden of age-related macular degeneration from 1990 to 2019:Results from the global burden of disease study 2019 AMD Drusen-oBRB oBRB VEGF CNV Bruch RPE 2009 1210 7 3 AMD AMBOSS VEGF 140 AMD AMD PhotoDynamic Therapy,PDT VEGF VEGF AMD VEGF VEGF 5 VEGF-A VEGF-B VEGF-C VEGF-D PLGF wAMD VEGF wAMD-2 Ang-2 VEGF Ang-2 Tie2 AMD AMD 2009 1210 8 4 AMD 5 VEGF AMD Harvard Medical School Hanna Heloter&Kai Kaarniranta A Linkage between Angiogenesis and Inflammation in Neovascular Age-Related Macular Degeneration wAMD VEGF Ranibizumab Aflibercept Brolucizumab Faricimab Conbercept 4 16 3-12 0.35-2.7 0.64-1.49 6 wAMD Ranibizumab Aflibercept Conbercept Brolucizumab Faricimab Lucentis Eylea Beovu Vabysmo 2006-06 2007-01 2011-12 2011-11 2012-11 2017-12 2013-11 2019-10 2020-02 2022-01 2022-09 2023-12 VEGF-A VEGFR VEGFR VEGF-A VEGF/Ang2 Fab scFv 0.3mg 0.5mg Q4W 3 2mg Q4W 2mg Q8W 0.5mg Q4W 0.5 mg Q12W 3 6mg Q4W 6mg Q8-12W 4 6mg Q4W,OCT 6mg Q16W/12 7/6 6/4 6/4 6/3 10mg/ml(0.2ml),3673.5 40mg/ml(0.1ml),4100 10mg/ml(0.2ml),3452.8 0.05ml:6mg,9000/0.66 0.3mg/1.44/1.23 0.52/0.35 5.4/2.7(Q16W)2009 1210 9 6mg/ml(0.05ml),1242 40mg/ml(0.05ml),1958 0.05ml:6mg,2077 0.05ml:6mg,2136/1.49 0.3mg/1.37/1.17 1.25/0.83 Q12W 1.28/0.64(Q16W)Drugs 2023 wAMD 140 19.36 7 wAMD 8 wAMD 2006 2011 FDA 42.9 2014 96.5 2022 2020 III 2023 12 2023 1 CDE 9 Biocon Teva Pharmaceutical CinnaGen Bioeq/Sandoz/Coherus BioSciences III Biogen/Celltrion III/STADA/Xbrane Biopharma Sam Chun Dang III Reliance Life Sciences Rophibio III/Senju Pharmaceutical III III Intas Pharmaceuticals Formycon/Coherus BioSciences III Generium III Sandoz III III III Alteogen III III III/III III Incepta Pharmaceuticals III III III Sun Pharmaceutical III 0204060801001201401602006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023阿柏西普 雷珠单抗布西珠单抗 法瑞西单抗051015202014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2009 1210 10 Samsung BioLogics/III Chong Kun Dang Pharmaceutical III Alvotech/Polifarma III Lupin III I Ligand Pharmaceuticals I/II I Rus Biopharm I/Binex I I inno.N I I I BIOCND I VEGF Best-Corrected Visual Acuity BCV A BCV A ETDRS BCV A ETDRS 5 15 15 BCV A central retinal thickness CRT OCT 10 ETDRS 11 OCT CRT ETDRS Snellen Yu Wakatsuki,et al.,Morphological Changes and Prognostic Factors before and after Photodynamic Therapy for Central Serous Chorioretinopathy 2009 1210 11 AMD VEGF VEGF AMD BCV A 12 wAMD FDA label VEGF 1 BCV A 7-11 1 BCV A-1 3 4 VEGF 6 1-4 7.5 6.7 6.6 6.4 VEGF 13 VEGF 14 VEGF Genentech VOYAGER:An Innovative Real-world Study of Faricimab and the Port Delivery System With Ranibizumab in Patients With nAMD and DME Ocular Therapeutics 康柏西普AMD-1 AMD-2 VIEW1 VIEW2 PHOENIX HAWK HARRIER TENAYA LUCERNE55.7/55.2 vs 54.0 51.6/52.8 vs 53.8 BCVA 24-73 60.8 vs 60.0 61.5 vs 60.8 61.3 vs 61.5 58.7 vs 58.9230 vs 229 139 vs 141 301/304 vs 340 306/309 vs 291 81 vs 43 360 vs 360 360 vs 360 334 vs 337 331 vs 32712 周BCVA 较基线平均变化 5.5 vs-15.0 10.9 vs-9.1 7.9/10.9 vs 8.1 8.9/7.6 vs 9.4 9.20 vs 2.02 6.6 vs 6.8 6.9 vs 7.6 5.8 vs 5.1 6.6 vs 6.6BCVA 下降15 个字母患者比例 89%vs 56%93%vs 65%94%/95%vs 94%95%/95%vs 95%BCVA 增加15个字母患者比例 30%vs 4%37%vs 9%31%/38%vs 31%31%/29%vs 34%33.6%vs 25.4%29.3%vs 29.9%康柏西普 vs 对照213 vs 43结膜出血 眼痛 0.0%vs 0.0%白内障 0.9%vs 0.0%玻璃体脱落 玻璃体漂浮物 1.4%vs 0.0%视力模糊 眼内炎症 0.5%vs 0.0%眼内压增高 4.7%vs 0.0%布西珠单抗 vs 阿柏西普 法瑞西单抗 vs 阿柏西普 安全性评估分组安全性数据疗效数据布西珠单抗：6mg Q4W 3，Q8/12W阿柏西普：2mg Q8W17%vs 5%康柏西普：0.5mg Q4W3，Q12W对照组：0.5mg 假注射 Q4W3，康柏西普0.5mg Q4W3，Q12W法瑞西单抗：6mg，Q4W 4，Q8/12W阿柏西普：2mg Q8W关键终点安全性评估人数 440 vs 441，1 年数据 1824 vs 595 730 vs 729 664 vs 662常见AEs雷珠单抗 vs 对照 阿柏西普 vs 雷珠单抗40、44、48周平均数据 48 周 疗效测量时间 52 周入组基线平均BCVA BCVA 18-7824 月试验设计阿柏西普：2mg Q8W/2mg Q4W雷珠单抗：0.5mg Q4W疗效评估人数雷珠单抗:0.5mgQ4W;对照组：假注射 Q4W雷珠单抗:0.5mg+假PDT Q4W对照组：VerteporfinPDT Q4W4%vs 3%3%vs 3%25%vs 28%6%vs 7%7%vs 8%4%vs 5%3%vs 2%2%vs 1%2%vs 3%2%vs 2%10%vs 11%2%vs 3%64%vs 50%26%vs 20%11%vs 9%15%vs 15%19%vs 5%13%vs 10%13%vs 7%获批临床名称阿柏西普 布西珠单抗 法瑞西单抗 雷珠单抗9%vs 9%5%vs 6%6%vs 6%6%vs 7%5%vs 3%3%vs 2%3%vs 2%7%vs 7%7%vs 11%2009 1210 12 15 Audrey Giocanti-Aur gan et al.,Drivers of and Barriers to Adherence to Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Treatment Management Plans:A Multi-National Qualitative Study,VEGF 1-2 AMD VEGF/Ang2 Vabysmo VEGF/Ang2 VEGF Ang2 VEGF Ang-2 VEGF wAMD 4 3 2009 1210 13 16 VEGF 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 2022 1 FDA wAMD DME 2023 10 RVO 2023 23.57 26 2024 1 wAMD DME 22%15%2022 2023 17 Vabysmo wAMD III TENAYA LUCERNE 1 6.0mg 4 4 20 24 8 12 16 2 2.0mg 3 4 8 40 44 48 BCV A TENAYA LUCERNE 1 5.8 6.6 5.1 6.6 3%2 4.4 1.521.903.404.755.787.228.189.320123456789102022Q2 2022Q3 2022Q4 2023Q1 2023Q2 2023Q3 2023Q4 2024Q1 2009 1210 14 4.3 16 18 TENAYA LUCERNE 19 Genentech Efficacy,Safety,and Durability of Faricimab in Neovascular Age-Related Macular Degeneration:Year 2 Results From the Phase 3 TENAYA and LUCERNE Trials Genentech Faricimab in Neovascular Age-Related Macular Degeneration:Year 2 Patient Case Profiles From the Phase 3 TENAYA and LUCERNE Trials Genentech VOYAGER VOYAGER wAMD 5/wAMD VOYAGER 174 220 wAMD 97.7%VEGF 46.4 2024 2 3 CST 20 VOYAGER 21 VOYAGER Genentech VOYAGER Study:Update on Faricimab in the Real World Genentech VOYAGER Study:Update on Faricimab in the Real World VEGF VEGF VEGFR/C1 IBI302 VEGFR/FGFR RC28 III 2009 1210 15 22 wAMD VEGF-A/Ang2 RC28 VEGFR/FGFR III III IBI302 VEGFR/C1 III III BI 836880 VEGF-A/Ang2 BI/I/II XMVA09 VEGF/Ang2 I/II I/II Y400 VEGF-A/Ang2 I/II I/II ASKG712 VEGF/Ang2/I I IBI333 VEGF-A/VEGF-C I I zifibancimig VEGF-A/Ang2 I ABP-201 VEGF/Ang2/Abpro IBI302 efdamrofusp alfa First-in-Class VEGF/VEGF wAMD II 360 IBI302 3 2023 10 IBI302 8mg wAMD III STAR 2024 3 19 wAMD IBI302 II 132 1:1:1 IBI302 6.4mg IBI302 8.0mg 2.0mg IBI302 8 12 2.0mg 8 52 40 BCV A 40 IBI302 6.4 mg 8.0 mg BCV A BCV A 10.5 11.0 9.8 CST-163.19-184.46-108.23 IBI302 12 88%81%8.0 mg PULSAR 83%TENAYA&LUCERNE 79.7%77.8%12 II III STAR IBI302 16 IBI302 IBI302 2009 1210 16 23 IBI302 wAMD II BCV A 24 IBI302 wAMD II CST VEGF VEGFR 25 wAMD AXPAXLI Ocular Therapeutix VEGFR/PDGFR Elutyx III EYP-1901 EyePoint/VEGFR/PDGFR Durasert II GB102 Graybug Vision VEGFR/PDGFR II CLS-AX Clearside Biomedical VEGFR/PDGFR II AIV007 AiViva Biopharma AIV007 VEGFR/PDGFR/FGFR/I EYP-1901 83%EYP-1901 EyePoint Pharmaceutical Durasert VEGFR/PDGFR 2023 6 8 NMPA EyePoint Pharmaceutical Durasert EYP-1901 Durasert 9 2020 2 Equinox Sciences EyePoint EyePoint wAMD DR RVO EyePoint EyePoint EYP-1901 2022 5 EyePoint 2009 1210 17 EYP-1901 EyePoint EYP-1901 2023 7 NMPA EYP-1901 pmCNV pmCNV VEGF EYP-1901 2024 4 EYP-1901 wAMD NMPA 26 27 EYE-1901 EyePoint Investor Presentation March 2024 EyePoint Investor Presentation March 2024 I DA VIO EYP-1901 SAE SAE Durasert AE 6 BCV A OCT 53%6 VEGF 2023 7 27 Eyepoint II DAVIO2 DAVIO2 EYP-1901 wAMD II EYP-1901 2mg 3mg EYP-1901 VEGF 12 10.2 10.0 9.5 2023 12 EyePoint DA VIO2 FDA-4.5 2mg 3mg EYP-1901 BCV A-0.3-0.4 28 DAVIO2 BCV A 29 DAVIO2 EyePoint Investor Presentation March 2024 EyePoint Investor Presentation March 2024 2009 1210 18 EYP-1901 2mg 3mg 89%85%83%79%1 BCV A 5 75 2 wAMD BCV A 10 3 100 4 wAMD 5 6 VEGF 65%64%EYP-1901 97%AEs 1 2 EYP-1901 SAE EYP-1901 30 DAVIO2 31 DAVIO2 EyePoint Investor Presentation March 2024 EyePoint Investor Presentation March 2024 DA VIO 2 12 2024 Eyepoint EYP-1901 wAMD III LUGANO LUCIA III 8 1 EYP-1901 6 4 52 56 BCV A 12 24 32 EYP-1901 III EyePoint Investor Presentation March 2024 2009 1210 19 AXPAXLI 12 89%AXPAXLI Ocular Therapeutix Elutyx 6 VEGFR/PDGFR TKI Ocular Therapeutix AXPAXLI wAMD DR Elutyx Elutyx Elutyx Dextenza FDA 33 AXPAXLI Ocular Therapeutix Corporate Presentation,January 2024 Ocular Therapeutix AXPAXLI wAMD I I NCT04989699 VEGF wAMD AXPAXLI 8 21 3:1 AXPAXLI 2023 4 14 AXPAXLI SAEs 12 AXPAXLI BCV A-1.0 CSFT+2.0-2009 1210 20 34 AXPAXLI I Ocular Therapeutix Corporate Presentation,January 2024 1 BCV A BCV A 10 BCV A 2 CSFT 75 m BCV A BCV A 5 3 AXPAXLI 8-9 60%12 12 4 AXPAXLI 12 89%35 AXPAXLI I 36 AXPAXLI I Ocular Therapeutix Corporate Presentation,January 2024 Ocular Therapeutix Corporate Presentation,January 2024 AXPAXLI wAMD III SOL-1 FDA 300 2 4 AXPAXLI VEGF 36 BCV A 15 2024 2 2009 1210 21 37 AXPAXLI III SOL Ocular Therapeutix Corporate Presentation,January 2024 VEGF VEGF ABBV-RGX-314 III 38 wAMD ABBV-RGX-314 VEGF/ReGenXBio III ixoberogene soroparvovec VEGFR Adverum Biotechnologies II LX102 VEGF II 4D-150 PIGF/VEGF-A/B/C 4DMT II NG101 Neuracle Genetics/Reyon Pharmaceutical I/II EXG102-031 VEGF/Ang2 I/II AL-001 VEGF I/II XMVA09 VEGF/Ang2 I/II SKG0106 VEGF I/II RRG001 VEGFR I/II KH631 VEGFR I/II FT-003 VEGF Frontera Therapeutics I/II JNJ-1887 CD59 I BD311 VEGF-A I 2009 1210 22 JWK001 VEGF I LX109 I KH658 VEGF I ABBV-RGX-314 wAMD ABBV-RGX-314 Regenxbio AA V8 VEGF Fab VEGF Fab RGX-314 ATMOSPHERE ASCENT subretinal wAMD II suprachoroidal wAMD AA VIATE DR ALTITUDE 2021 9 13 AbbVie Regenxbio ABBV-RGX-314 AbbVie Regenxbio 3.7 13.8 AbbVie Regenxbio Regenxbio RGX-314 AbbVie RGX-314 39 ABBV-RGX-314 Regenxbio Suprachoroidal Delivery of Investigational ABBV-RGX-314 for Neovascular AMD:Results from the Phase II AAVIATE Study Regenxbio Form 8-K AA VIATE II ABBV-RGX-314 wAMD ABBV-RGX-314 40 BCVA ABBV-RGX-314 2.5 1011 5 1011 1 1012 GC/VEGF 9.7 8.8 8.9 ABBV-RGX-314 6 BCV A CRT VEGF 3 80%2009 1210 23 50%CNV 5 2023 11 6 106 ABBV-RGX-314 SAE 6 TEAEs 1 2 3 3 6 n=21 ABBV-RGX-314 40 AAVIATE 41 AAVIATE Regenxbio Suprachoroidal Delivery of Investigational ABBV-RGX-314 for Neovascular AMD:Results from the Phase II AAVIATE Study Regenxbio Suprachoroidal Delivery of Investigational ABBV-RGX-314 for Neovascular AMD:Results from the Phase II AAVIATE Study I/IIa RGX-314 3 6 1010GC/RGX-314 6 4 67%4 1.6 1011GC/12 3 58%5 2.5 1011GC/12 2 78%42 RGX-314 I/IIa Regenxbio Presentation at AAO 2022 3 4 ATMOSPHERE ASCENT 1200 wAMD 2025 2026 2009 1210 24 43 RGX-314 Regenxbio Corporate Presentation April 2024 ADVM-022 94%ADVM-022 Ixoberogene soroparvovec Ixo-vec Adverum wAMD ADVM-022 AA V.7m8 44 ADVM-022 Adverum Virtual KOL/IR Event,November 14,2020 II LUNA 60 1:1 1 1 6 1010 vg/2 1011 vg/ADVM-022 VEGF 10.0 9.7 BCV A 72.9 71.8 2009 1210 25 45 LUNA Adverum Corporate Presentation April 2024 26 VEGF 90%n=19 94%n=20 68%85%26 VEGF BCV A 10 CST 75 m AMD BCV A+0.5-1.7 CST-7.9-16.4 m 46 LUNA 47 LUNA BCV A CST Adverum Corporate Presentation April 2024 Adverum Corporate Presentation April 2024 2 3 I OPTIC 3 ADVM-022 4D-150 63%VEGF 4D-150 4D Molecular Therapeutics R100 VEGF-C RNAi wAMD DME VEGF VEGF-A/B/C PIGF 2009 1210 26 48 4D-150 4DMT Corporate Presentation April 2024 II PRISM 110 wAMD 4D-150 PRISM n=15 n=41 n=32 SPECTRA n=22 PRISM 51 CST 442 m 3.1 2:2:1 20 21 3 1010 vg/1 1010 vg/4D-150 10 8 2mg 12 VEGF 9.9 9.4 9.3 9.6 49 I/II PRISM 4DMT Corporate Presentation April 2024 24 2024 1 19 4D-150 VEGF 89%85%PRISM 1 BCV A 2009 1210 27 7 1 10 2 CST 7 1 75 3 wAMD 6 63%50%84%90%4D-150 20 24 BCVA-1.8+1.8 CST-8.3+29.9 4D-150 CST 50 PRISM BCV A 51 PRISM CST 4DMT Corporate Presentation April 2024 4DMT Corporate Presentation April 2024 4D-150 SAE SAE 4DMT FDA EMA III 4D-150 3 1010 vg/2025 PRISM 16 4D-150 6 III 4D-150 20 24 BCV A+3.3 CST-99.0 4D-150 90%63%88%0-1 III 52 PRISM III 4D Molecular Therapeutics Corporate Presentation April 2024 2009 1210 28 LX102 6 91%LX102 wAMD AA V VEGF DNA VEGF LX102 2022 12 23 CDE 2023 12 22 FDA 2023 12 20 LX102 II wAMD Angiogenesis,Exudation,and Degeneration 2024 LX102 wAMD IIT 1-2 I LX102 20 LX102 18 I LX102 9/9 VEGF 71 LX102 VEGF 89 LX102 6 1/11 wAMD IIT 18-24 0/6 53 LX102 wAMD KH631&KH658 KH631 AA V8 VEGF wAMD KH631 VEGFR1 2 VEGFR2 3 4 IgG1 Fc 2009 1210 29 VEGFR VEGF-A VEGF-B PlGF KH631 RPE KH631 KH631 10.9 141.1 KH631 CNV 3 108 vg/KH631 IV KH631 96 2022 11 KH631 NMPA FDA 54 KH631 Xiao Ke et al.Preclinical evaluation of KH631,a novel rAAV8 gene therapy product for neovascular age-related macular degeneration 2024 4 KH658 CDE FDA I/II KH658 KH658 VEGF VEGF AMD BCV A VEGF 1-2 VEGF/Ang 16 3 26 2009 1210 30 VEGF VEGFR EYP-1901 AXPAXLI 6 VEGF 89%60-65%6-12 AXPAXLI III EYP-1901 2024 III Eyepoint EYP-1901 EYP-1901 VEGF VEGF RGX-314 4D-150 VEGF 80%50%ABBV-RGX-314 III 2025 2026 4D-150 2025 III 2027-2028 Eyepoint/Regenxbio Ocular Therapeutix 4D Molecular Therapeutics Adverum 55 wAMD Adverum Corporate Presentation April 2024 2009 1210 31 56 wAMD 57 wAMD 58 wAMD EYP-1901 AXPAXLI ABBV-RGX-314 ADVM-022 4D-150EyePoint/贝达药业 Ocular Therapeutix Regenxbio/艾伯维 Adverum 4DMT小分子缓释剂 小分子缓释剂 基因疗法 基因疗法 基因疗法VEGFR/PDGFR VEGFR/PDGFR VEGF VEGF VEGF-A/B/C、PIGFDAVIO2 NCT04989699 AAVIATE LUNA PRISM 剂量扩展试验II 期 I 期 II 期 II 期 II 期给药方案 第8周1 剂，2mg/3mg 第4 周1 剂第2周1剂，2.5E11、5E11 或1E12 GC/眼6E10vg/眼或2E11 vg/眼1E10 vg/眼或3E10 vg/眼（脉络膜上腔给药）患者人数 53/54 14 15/35/56 30/30 20/21患者BCVA基线 73.9/74.9 73.7 75.1/71.9/72.8 72.9/71.8 71/68阿柏西普 2mg Q8W 阿柏西普 2mg Q8W 雷珠单抗 阿柏西普 2mg Q8W第28、32 周平均 52周 24 周 第26 周 第20、24 周平均BCVA较基线变化(治疗组vs对照组),字母数+1.0/+0.9 vs+1.3-1.0 vs+2.0-2.8/-1.0/-2.2 vs+4.0+0.5/-1.7+1.8/-1.8(较阿柏西普